Nonmyeloablative conditioning generates autoantigen-encoding bone marrow that prevents and cures an experimental...

Area of Science:

• Immunology
• Gene Therapy
• Neuroscience

Background:

• Autoimmune diseases involve chronic immune responses causing tissue damage.
• Autologous hematopoietic stem cell transplantation (HSCT) is a potential treatment, but disease relapse is a concern.
• Previous studies showed MOG-engineered bone marrow (BM) transplantation prevents experimental autoimmune encephalomyelitis (EAE) in mice, but required lethal irradiation.

Purpose of the Study:

• To assess the efficacy of nonmyeloablative conditioning using treosulfan for HSCT in treating autoimmune diseases.
• To determine if low-level chimerism induced by treosulfan-based HSCT can prevent and reverse EAE.
• To evaluate the feasibility of gene therapy for autoimmune disease using reduced toxicity protocols.

Main Methods:

• Generated bone marrow chimeras using treosulfan as a nonmyeloablative agent.
• Transduced bone marrow to encode the autoantigen myelin oligodendrocyte glycoprotein (MOG).
• Assessed the protective and curative effects in mouse models of EAE induction and reversal.

Main Results:

• Treosulfan conditioning induced sufficient low-degree chimerism for antigen-specific tolerance.
• This low chimerism protected mice from EAE induction.
• Nonmyeloablative conditioning and low chimerism were effective in reversing established EAE, maintaining disease resistance.

Conclusions:

• Nonmyeloablative conditioning with treosulfan enables successful antigen-specific tolerance induction via HSCT.
• This gene therapy approach is feasible for preventing and treating autoimmune diseases like EAE.
• These findings support the potential of gene-modified HSCT as a safer therapeutic strategy for autoimmunity.